trending Market Intelligence /marketintelligence/en/news-insights/trending/RacnD0686Fhg4xBLmBRUXA2 content esgSubNav
In This List

Syndax Pharmaceuticals plans $25M direct offering

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Syndax Pharmaceuticals plans $25M direct offering

Syndax Pharmaceuticals Inc. agreed to sell 2,021,018 shares to Biotechnology Value Fund LP and certain affiliates in a registered direct offering.

The company is expecting about $25 million in gross proceeds based on an offering price of $12.37 per share, which is the closing price of Syndax's shares on the Nasdaq Global Select Market on Oct. 13.

BTIG LLC served as a capital markets advisor to Syndax in connection with the offering.